We are cured, again (again) : It was on the... - AMN EASIER

AMN EASIER

1,324 members1,179 posts

We are cured, again (again)

monkeybus profile image
3 Replies

It was on the website, myelin.org (now defunct), that I first learned about Sobetrirome and it's role in upregulating ABCD2.

I believe myelin.org was run by Lorenzo Odone's parents. It was there that I first read about Ampyra as well. But, I digress.

It was originally envisaged that sobetirome could be used to stimulate hepatic pathways that lower cholesterol without harmful side effects and might be used in conjunction with statins.

Obviously, they didn't bother with Sobetrirome, and just went with statins to lower cholesterol levels.

There is evidence for Lovastatin lowering VLCFA levels.

adrenoleukodystrophy.info/t....

Just not good enough.

But, how about Sob-AM2?

Sob-AM2 delivers a more potent and effective therapy for the most common type of ALD – adrenomyeloneuropathy (AMN) – than the original drug sobetirome.

Sob-AM2 is a chemical compound created from sobetirome.

blogs.ohsu.edu/researchnews...

ncbi.nlm.nih.gov/pmc/articl...

Lowers ABCD2 and promotes remyelination.

Here is a long copy/paste:

"Sobetirome and Sob-AM2 work because they activate or upregulate ABCD2, a gene which is classically thyroid hormone-regulated,” said Scanlan.

In their dose-response study, the team treated ABCD1-deficient mice with Sob-AM2, which activated ABCD2 to correct the ABCD1 defects. They measured the levels of VLCFAs in the brain and spinal cord, as well as blood and organs.

“We found that Sob-AM2 was more potent than sobetirome at reducing elevated VLCFA in the CNS, particularly in the spinal cord which is relevant for AMN,” said Scanlan. “Sob-AM2 also reduced elevated VLCFA in blood and peripheral tissue, but not as potently as sobetirome, which makes sense because Sob-AM2 targets the CNS and sobetirome targets the periphery.”

The findings established that Sob-AM2 provides significant and sustained reductions to the elevated levels of VLCFA that are responsible for the pathology in ALD. The next step is clinical trials in patients.

Looks very promising indeed.

Written by
monkeybus profile image
monkeybus
To view profiles and participate in discussions please or .
Read more about...
3 Replies
artortega78 profile image
artortega78

Yes it does. Sob-AM2 needs to be approved by the FDA in at least 3 years from now after the clinical trials are finished.

Abcd1Kat profile image
Abcd1Kat

FYI: the Myelin Project merged into ALD Connect in 2019 so not really “defunct,” just working under a different name 💙. As for Sob-AM2, I am hopeful that it’s advancing down the pipeline to trial🤞

monkeybus profile image
monkeybus in reply toAbcd1Kat

myelin.org was a great domain name. They should have kept it.

Not what you're looking for?

You may also like...

REDUCING VLCFA COULD REDUCE SPASMS AND OTHER SYMPTOMS OF AMN.

I have been researching the literature on AMN and XALD for some time, and have decided to write...
ROBSUPERNOVA profile image

Hi, I'm new

My name is Zach. Addison's was confirmed 4 days ago and AMN was confirmed (from a VLCFA test) 2...
tetris profile image

Valproic Acid

I've just persuaded my neurologist to prescribe me some Valproic Acid. Surprisingly easy, but...
monkeybus profile image

Gene Therapy and remyelination as a cure

Hello all, A good friend of mine was diagnosed yesterday with AMN. He already started having...
diderot555 profile image

Urinary Urgency: life becoming intolerable

Hello, I wanted to ask a question about urinary urgency [I know the subject has been done to death...
jack3953 profile image

Moderation team

COwithAMN profile image
COwithAMNAdministrator

Content on HealthUnlocked does not replace the relationship between you and doctors or other healthcare professionals nor the advice you receive from them.

Never delay seeking advice or dialling emergency services because of something that you have read on HealthUnlocked.